Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Bictegravir Sodium
2. Gs-9883
3. Gs-9883 Sodium
4. Gs-9883-01
5. Gs-9883-01 Sodium
1. 1611493-60-7
2. Gs-9883
3. Bictegravir [inn]
4. Gs-9883-01
5. (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
6. 8gb79loj07
7. (1s,11r,13r)-5-hydroxy-3,6-dioxo-n-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
8. 2,5-methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-n-((2,4,6-trifluorophenyl)methyl)-, (2r,5s,13ar)-
9. Bictegravir [usan:inn]
10. Bictegravirum
11. Unii-8gb79loj07
12. Gs 9883
13. Bictegravir [mi]
14. Bictegravir (usan/inn)
15. Bictegravir [usan]
16. Bictegravir [who-dd]
17. Chembl3989866
18. Schembl15914278
19. Gtpl11575
20. Chebi:172943
21. Bdbm330048
22. Dtxsid701027937
23. Amy12383
24. Bcp25703
25. Ex-a3161
26. Gs9883
27. S5911
28. Db11799
29. Dt-0020
30. Ac-30658
31. Hy-17605
32. Cs-0014685
33. D10909
34. N16998
35. Us9663528, 42
36. A902376
37. Q27270406
38. Gs-9883; Gs 9883; Gs9883; Gs-9883-01
39. (1s,11r,13r)-5-hydroxy-3,6-dioxo-n-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0(2),(1)(1).0?,?]hexadeca-4,7-diene-7-carboxamide
40. (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazepine-10-carboxamide
Molecular Weight | 449.4 g/mol |
---|---|
Molecular Formula | C21H18F3N3O5 |
XLogP3 | 2.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 3 |
Exact Mass | 449.11985517 g/mol |
Monoisotopic Mass | 449.11985517 g/mol |
Topological Polar Surface Area | 99.2 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 912 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Bictegravir is indicated in the management of HIV-1 infection in patients not previously treated with antiretroviral therapy. Additionally, Bictegravir is indicated in the management of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA <50 c/mL) on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication. It is used in combination with tenofovir and emtricitabine.
FDA Label
Bictegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Bictegravir (BIC) inhibits HIV-1 virus replication into the human genome. It can be taken once daily without additional dosing. Bictegravir (BIC) inhibits strand transfer of viral DNA into the host genome and thereby prevents HIV-1 replication.
Absorption
Bictegravir is rapidly absorbed within the body. Tmax= 2.0-4.0h [FDA LABEL, 1219]
Route of Elimination
BIC is mainly eliminated through UGT1A1 glucuronidation and CYP3A4 oxidation, equally. About 1% of the bictegravir dose is excreted in the urine, unchanged [1218,1219].
Volume of Distribution
0.2 L/Kg in humans
Clearance
Bictegravir is mainly cleared by the kidneys. Those with renal clearance <30 should not take bictegravir [FDA LABEL]
In a 10-day dose-ranging study, monotherapy (5 mg to 100 mg) once daily in adults who were not previously treated with bictegravir, the median half-life of BIC ranged from 15.9 h - 20.9 h [L1219. Bictegravir is metabolized in the liver and kidneys. CYP3A4 and UGT1A are the primary enzymes involved in the metabolism of bictegravir. Administration of bictegravir is not advised in patients with renal creatinine clearance of <30 mL/min and patients with hepatic disease [FDA LABEL].
17. 3h [FDA LABEL, L1219]
This single dose medication inhibits the strand transfer of viral DNA into the human genome, preventing HIV-1 virus replication and propagation. In vitro, bictegravir has shown powerful antiviral activity against HIV-2 and various subtypes of HIV-1. It has shown synergistic effects when combined with other ARVs, including tenofovir alafenamide (TAF), emtricitabine (FTC), and darunavir (DRV) [FDA LABEL]. The three components of the first USA approved medication ( trade name: Biktarvy ) are as follows: Bictegravir: integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme necessary for viral replication. Inhibition of the integrase enzyme prevents the integration of HIV-1 into host DNA, blocking the conversion of the HIV-1 provirus and progression of the virus [FDA LABEL]. Emtricitabine: FTC, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate intracellularly. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase by competing with the substrate deoxycytidine 5'-triphosphate and by incorporating itself into viral DNA preventing DNA chain elongation [FDA LABEL]. Tenofovir Alafenamide: TAF is a phosphonamidate prodrug of tenofovir (2-deoxyadenosine monophosphate analog). Plasma exposure to TAF leads to leakage into cells and then TAF is intracellularly converted to tenofovir by hydrolysis by cathepsin. Tenofovir is subsequently phosphorylated by cellular kinases to the metabolite tenofovir diphosphate, which is the active form of the drug. Tenofovir diphosphate inhibits HIV-1 replication by incorporating into viral DNA by the HIV reverse transcriptase, resulting in DNA chain-termination. Tenofovir diphosphate also weakly inhibits mammalian DNA polymerases [FDA LABEL].
Global Sales Information
ABOUT THIS PAGE
A Bictegravir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bictegravir, including repackagers and relabelers. The FDA regulates Bictegravir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bictegravir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bictegravir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bictegravir supplier is an individual or a company that provides Bictegravir active pharmaceutical ingredient (API) or Bictegravir finished formulations upon request. The Bictegravir suppliers may include Bictegravir API manufacturers, exporters, distributors and traders.
click here to find a list of Bictegravir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bictegravir DMF (Drug Master File) is a document detailing the whole manufacturing process of Bictegravir active pharmaceutical ingredient (API) in detail. Different forms of Bictegravir DMFs exist exist since differing nations have different regulations, such as Bictegravir USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bictegravir DMF submitted to regulatory agencies in the US is known as a USDMF. Bictegravir USDMF includes data on Bictegravir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bictegravir USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bictegravir suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bictegravir as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bictegravir API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bictegravir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bictegravir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bictegravir NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bictegravir suppliers with NDC on PharmaCompass.
Bictegravir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bictegravir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bictegravir GMP manufacturer or Bictegravir GMP API supplier for your needs.
A Bictegravir CoA (Certificate of Analysis) is a formal document that attests to Bictegravir's compliance with Bictegravir specifications and serves as a tool for batch-level quality control.
Bictegravir CoA mostly includes findings from lab analyses of a specific batch. For each Bictegravir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bictegravir may be tested according to a variety of international standards, such as European Pharmacopoeia (Bictegravir EP), Bictegravir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bictegravir USP).
LOOKING FOR A SUPPLIER?